TARGETED THERAPY

This study tests whether adding radiotherapy to a drug combination (fruquintinib and sintilimab) can help control colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. About 62 adults with a specific cancer subtype (MSS/pMMR) will be randoml…

This study tests whether adding low-dose radiation to standard targeted therapy and immunotherapy before surgery helps shrink head and neck tumors more effectively than the drugs alone. About 98 adults with operable head and neck squamous cell carcinoma will be randomly assigned …

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation, chemotherapy, and a targeted therapy) can improve outcomes for people with locally advanced rectal cancer. About 104 adults with a specific type of rectal …

This study aims to find the best treatment before surgery for people with esophageal or stomach cancer. It compares chemotherapy, chemoradiation, targeted therapy, and immunotherapy. The goal is to improve survival and reduce side effects. About 2000 adults with stage I to IVa ca…

This study tests whether combining olutasidenib with other targeted drugs is safe and tolerable for adults with relapsed or hard-to-treat blood cancers (like AML or MDS) that have both an IDH1 mutation and an additional signaling mutation. About 68 participants will receive the d…

This study aims to find the best treatment plan for people with esophageal or esophagogastric junction cancer that cannot be removed by surgery. It will test adding immunotherapy (PD-1/PD-L1 antibodies) or targeted drugs to the standard chemoradiotherapy. About 2000 adults with s…

This study is testing a new supportive care program called POISE for people with stage IV non-small cell lung cancer who are on targeted therapy. The program includes four visits with a specially trained palliative care clinician to help patients cope with uncertainty and manage …

This study looks at whether a patient's emotional state—like depression or anxiety—can influence how well advanced liver cancer responds to a combination of chemotherapy, targeted therapy, and immunotherapy. Researchers will follow 90 adults with BCLC stage B or C liver cancer, g…

This early-stage study tests a new drug called SOB100 in 15 healthy adults. SOB100 is a tiny particle (exosome) designed to target a protein called HLA-G. The main goal is to check if it is safe and how the body processes it. No treatment benefit is expected for participants.